Literature DB >> 20516601

Crystallization and preliminary X-ray analysis of Ebola VP35 interferon inhibitory domain mutant proteins.

Daisy W Leung1, Dominika Borek, Mina Farahbakhsh, Parameshwaran Ramanan, Jay C Nix, Tianjiao Wang, Kathleen C Prins, Zbyszek Otwinowski, Richard B Honzatko, Luke A Helgeson, Christopher F Basler, Gaya K Amarasinghe.   

Abstract

VP35 is one of seven structural proteins encoded by the Ebola viral genome and mediates viral replication, nucleocapsid formation and host immune suppression. The C-terminal interferon inhibitory domain (IID) of VP35 is critical for dsRNA binding and interferon inhibition. The wild-type VP35 IID structure revealed several conserved residues that are important for dsRNA binding and interferon antagonism. Here, the expression, purification and crystallization of recombinant Zaire Ebola VP35 IID mutants R312A, K319A/R322A and K339A in space groups P6(1)22, P2(1)2(1)2(1) and P2(1), respectively, are described. Diffraction data were collected using synchrotron sources at the Advanced Light Source and the Advanced Photon Source.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20516601      PMCID: PMC2882771          DOI: 10.1107/S1744309110013266

Source DB:  PubMed          Journal:  Acta Crystallogr Sect F Struct Biol Cryst Commun        ISSN: 1744-3091


  18 in total

1.  A C-terminal basic amino acid motif of Zaire ebolavirus VP35 is essential for type I interferon antagonism and displays high identity with the RNA-binding domain of another interferon antagonist, the NS1 protein of influenza A virus.

Authors:  Amy L Hartman; Jonathan S Towner; Stuart T Nichol
Journal:  Virology       Date:  2004-10-25       Impact factor: 3.616

2.  Ebola virus: the role of macrophages and dendritic cells in the pathogenesis of Ebola hemorrhagic fever.

Authors:  Mike Bray; Thomas W Geisbert
Journal:  Int J Biochem Cell Biol       Date:  2005-03-07       Impact factor: 5.085

Review 3.  Entropy and surface engineering in protein crystallization.

Authors:  Zygmunt S Derewenda; Peter G Vekilov
Journal:  Acta Crystallogr D Biol Crystallogr       Date:  2005-12-14

4.  HKL-3000: the integration of data reduction and structure solution--from diffraction images to an initial model in minutes.

Authors:  Wladek Minor; Marcin Cymborowski; Zbyszek Otwinowski; Maksymilian Chruszcz
Journal:  Acta Crystallogr D Biol Crystallogr       Date:  2006-07-18

5.  Thermofluor-based high-throughput stability optimization of proteins for structural studies.

Authors:  Ulrika B Ericsson; B Martin Hallberg; George T Detitta; Niek Dekker; Pär Nordlund
Journal:  Anal Biochem       Date:  2006-08-10       Impact factor: 3.365

Review 6.  Universal screening methods and applications of ThermoFluor.

Authors:  Maxwell D Cummings; Michael A Farnum; Marina I Nelen
Journal:  J Biomol Screen       Date:  2006-08-30

7.  The role of entropy and polarity in intermolecular contacts in protein crystals.

Authors:  Marcin Cieślik; Zygmunt S Derewenda
Journal:  Acta Crystallogr D Biol Crystallogr       Date:  2009-04-18

8.  Structural basis for dsRNA recognition and interferon antagonism by Ebola VP35.

Authors:  Daisy W Leung; Kathleen C Prins; Dominika M Borek; Mina Farahbakhsh; JoAnn M Tufariello; Parameshwaran Ramanan; Jay C Nix; Luke A Helgeson; Zbyszek Otwinowski; Richard B Honzatko; Christopher F Basler; Gaya K Amarasinghe
Journal:  Nat Struct Mol Biol       Date:  2010-01-17       Impact factor: 15.369

9.  Structure of the Ebola VP35 interferon inhibitory domain.

Authors:  Daisy W Leung; Nathaniel D Ginder; D Bruce Fulton; Jay Nix; Christopher F Basler; Richard B Honzatko; Gaya K Amarasinghe
Journal:  Proc Natl Acad Sci U S A       Date:  2009-01-02       Impact factor: 11.205

10.  The Ebola virus VP35 protein inhibits activation of interferon regulatory factor 3.

Authors:  Christopher F Basler; Andrea Mikulasova; Luis Martinez-Sobrido; Jason Paragas; Elke Mühlberger; Mike Bray; Hans-Dieter Klenk; Peter Palese; Adolfo García-Sastre
Journal:  J Virol       Date:  2003-07       Impact factor: 5.103

View more
  5 in total

1.  Structural basis for Marburg virus VP35-mediated immune evasion mechanisms.

Authors:  Parameshwaran Ramanan; Megan R Edwards; Reed S Shabman; Daisy W Leung; Ariel C Endlich-Frazier; Dominika M Borek; Zbyszek Otwinowski; Gai Liu; Juyoung Huh; Christopher F Basler; Gaya K Amarasinghe
Journal:  Proc Natl Acad Sci U S A       Date:  2012-11-26       Impact factor: 11.205

2.  Global phosphoproteomic analysis of Ebola virions reveals a novel role for VP35 phosphorylation-dependent regulation of genome transcription.

Authors:  Andrey Ivanov; Palaniappan Ramanathan; Christian Parry; Philipp A Ilinykh; Xionghao Lin; Michael Petukhov; Yuri Obukhov; Tatiana Ammosova; Gaya K Amarasinghe; Alexander Bukreyev; Sergei Nekhai
Journal:  Cell Mol Life Sci       Date:  2019-09-28       Impact factor: 9.261

3.  In silico and in vitro methods to identify ebola virus VP35-dsRNA inhibitors.

Authors:  Jason G Glanzer; Brendan M Byrne; Aaron M McCoy; Ben J James; Joshua D Frank; Greg G Oakley
Journal:  Bioorg Med Chem       Date:  2016-09-04       Impact factor: 3.641

4.  dsRNA binding characterization of full length recombinant wild type and mutants Zaire ebolavirus VP35.

Authors:  Luca Zinzula; Francesca Esposito; Daniela Pala; Enzo Tramontano
Journal:  Antiviral Res       Date:  2012-01-25       Impact factor: 5.970

5.  A cryptic pocket in Ebola VP35 allosterically controls RNA binding.

Authors:  Matthew A Cruz; Thomas E Frederick; Upasana L Mallimadugula; Sukrit Singh; Neha Vithani; Maxwell I Zimmerman; Justin R Porter; Katelyn E Moeder; Gaya K Amarasinghe; Gregory R Bowman
Journal:  Nat Commun       Date:  2022-04-27       Impact factor: 17.694

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.